Use of Repaglinide During the First Weeks of Pregnancy in Two Type 2 Diabetic Women
- Angela Napoli, MD,
- Francesca Ciampa, MD,
- Antonietta Colatrella, MD and
- Francesco Fallucca, MD
- From the 2nd Faculty of Medicine, Department of Clinical Sciences, University “La Sapienza” Rome, Rome, Italy
- Address correspondence to Dr. Angela Napoli, Diabetes Unit, Hospital S. Andrea, Department of Clinical Sciences, 2nd Faculty of Medicine, University “La Sapienza ” Rome, via di Grottarossa 1035-1039, 00189 Rome, Italy. E-mail: angela.napoli{at}uniroma1.it
Repaglinide, the only glinide available in Italy, is a secretagogue developed for type 2 diabetes (1). There is no evidence about its use during human pregnancy. Studies on rats that showed its effects on long bone growth excluded any teratogenity (2). More data exist regarding the safety of metformin in pregnancy, even though it is not recommended as an oral hypoglycemic agent in diabetic pregnancy (3,4).
We report two case subjects of type 2 diabetic women who used repaglinide at conception and during the first 6–7 weeks …
